全文获取类型
收费全文 | 1223篇 |
免费 | 96篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 58篇 |
妇产科学 | 8篇 |
基础医学 | 96篇 |
口腔科学 | 29篇 |
临床医学 | 184篇 |
内科学 | 209篇 |
皮肤病学 | 16篇 |
神经病学 | 30篇 |
特种医学 | 248篇 |
外科学 | 184篇 |
综合类 | 23篇 |
预防医学 | 42篇 |
眼科学 | 7篇 |
药学 | 47篇 |
中国医学 | 5篇 |
肿瘤学 | 136篇 |
出版年
2023年 | 9篇 |
2021年 | 14篇 |
2020年 | 7篇 |
2019年 | 10篇 |
2018年 | 30篇 |
2017年 | 19篇 |
2016年 | 22篇 |
2015年 | 35篇 |
2014年 | 33篇 |
2013年 | 30篇 |
2012年 | 43篇 |
2011年 | 31篇 |
2010年 | 44篇 |
2009年 | 61篇 |
2008年 | 47篇 |
2007年 | 26篇 |
2006年 | 32篇 |
2005年 | 32篇 |
2004年 | 24篇 |
2003年 | 28篇 |
2002年 | 23篇 |
2001年 | 26篇 |
2000年 | 27篇 |
1999年 | 23篇 |
1998年 | 52篇 |
1997年 | 53篇 |
1996年 | 66篇 |
1995年 | 49篇 |
1994年 | 43篇 |
1993年 | 47篇 |
1992年 | 18篇 |
1991年 | 9篇 |
1990年 | 16篇 |
1989年 | 35篇 |
1988年 | 30篇 |
1987年 | 34篇 |
1986年 | 34篇 |
1985年 | 23篇 |
1984年 | 16篇 |
1983年 | 9篇 |
1982年 | 24篇 |
1981年 | 17篇 |
1980年 | 8篇 |
1979年 | 4篇 |
1978年 | 5篇 |
1977年 | 12篇 |
1976年 | 11篇 |
1975年 | 13篇 |
1970年 | 5篇 |
1967年 | 4篇 |
排序方式: 共有1326条查询结果,搜索用时 46 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
3.
4.
5.
Prostate cancer selectively metastasizes to the axial skeleton to produce osteoblastic lesions, which suggests that bidirectional paracrine interactions exist between prostate cancer and bone cells. To evaluate the role of tumor-stromal cell interaction and stromal-specific growth factors in prostate cancer growth and dissemination, we coinoculated nontumorigenic human prostate cancer cells (LNCaP) and various tissue-specific fibroblasts subcutaneously in athymic mice. LNCaP tumors were induced most consistently by human bone fibroblasts (62%), followed by two prostate fibroblast cell lines (31% and 17%), but not by lung, kidney, or embryonic 3T3 fibroblasts. Carcinomas formed preferentially in male hosts, demonstrating in vivo androgen sensitivity. Immunohistochemical and biochemical techniques confirmed the human prostate component of these tumors and were paralleled by elevations in serum prostate specific antigen. In vitro mitogenic assays revealed a two-to three-fold bidirectional stimulation between LNCaP and bone or prostate fibroblast conditioned media, but not lung, kidney, or 3T3 fibroblast conditioned media. A novel method developed to deliver concentrated bone or prostate fibroblast conditioned media in vivo using a slowly absorbed matrix (gelfoam) also induced tumor formation, emphasizing the importance of fibroblast growth factors in LNCaP tumor formation. Northern analysis identified the stromal compartment as the primary source of extracellular matrix (collagen, fibronectin), while only LNCaP cells expressed transforming growth factor alpha. Although LNCaP and stromal cells express basic fibroblast growth factor (bFGF), the bidirectional paracrine-mediated mitogenic activity between these cells is not inhibited by anti-bFGF antibodies, suggesting that other undefined growth factors may be involved in stimulating LNCaP growth. These observations illustrate the importance of stromal-epithelial interaction in prostate tumor growth and suggest that extracellular matrix and paracrine-mediated growth factors play a role in prostate cancer growth and metastasis. 相似文献
6.
7.
8.
9.
10.